American Journal of Pharmacological Sciences
ISSN (Print): 2327-6711 ISSN (Online): 2327-672X Website: http://www.sciepub.com/journal/ajps Editor-in-chief: Srinivas NAMMI
Open Access
Journal Browser
Go
American Journal of Pharmacological Sciences. 2014, 2(5), 82-86
DOI: 10.12691/ajps-2-5-2
Open AccessArticle

Role of L-carnitine and Coenzyme Q10 as Adjuvant Therapy in Patients with Type 2 Diabetes Mellitus

Noor Kadhim Mohammed-Jawad1, , May Al- Sabbagh2 and Kaiss A. AL-Jezaeri3

1Department of Clinical Pharmacy, Pharmacy College, Basra University, Basra, Iraq

2Department of Clinical Pharmacy, Pharmacy College, Baghdad University, Baghdad, Iraq

3Department of medicine, Al-Basra General Hospital

Pub. Date: October 12, 2014

Cite this paper:
Noor Kadhim Mohammed-Jawad, May Al- Sabbagh and Kaiss A. AL-Jezaeri. Role of L-carnitine and Coenzyme Q10 as Adjuvant Therapy in Patients with Type 2 Diabetes Mellitus. American Journal of Pharmacological Sciences. 2014; 2(5):82-86. doi: 10.12691/ajps-2-5-2

Abstract

Objective: To assess the effects of administration of L-carnitine and coenzyme Q10 on glycemic control, lipid profile and lipoprotein (a) when added to pre-existing oral antidiabetic drugs in patients with type 2 diabetes. Methods: Fifty seven type 2 diabetic patients were randomly assigned into three groups for treatment with L-carnitine (1g daily), coenzyme Q10 (150mg daily), orcontinued on the same oral antidiabetic drugs (sulfonylurea and metformin) and considered as control group. All patients have been kept on the same medications throughout the study. Patients followed up after 8 weeks of treatment. Fasting blood glucose, glycated hemoglobin(HbA1c), total cholesterol, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c) and lipoprotein (a) measured at baseline and after 8 weeks. Results: There is significant decrease in fasting blood glucose, total cholesterol, LDL-c and lipoprotein (a) in both L-carnitine group and coenzyme Q10 group after 8 weeks of treatment. In addition HbA1c% significantly decreased in coenzyme Q10 group compared to control group. There were no significant differences in HDL-c in all three groups. Conclusion: Supplementation with L-carnitineor coenzyme Q10 improve glycemic control in type 2 diabetic subjects when added to conventional antidiabetic medications and could help in reducing the risk of cardiovascular complications by reduction of LDL-cholesterol and lipoprotein (a).

Keywords:
L-carnitine Coenzyme Q10 type 2 diabetes glycemic control lipid profile lipoprotein (a)

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2014; 37 (1): 81-90.
 
[2]  Sicree R, Shaw j and Zimmet p. Diabetes and Impaired Glucose Tolerance. IDFDiabetes Atlas, fourth edition, 2009.
 
[3]  Hu F. B. Globalization of Diabetes The role of diet, lifestyle, and genes. Diabetes care 2011; 34(6): 1249-1257.
 
[4]  Guariguata L, Whiting D. R, Hambleton I, Beagley J, Linnenkamp U and Shaw J. E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice 2014; 103(2):137-149.
 
[5]  Soumya D. Late Stage Complications of Diabetes and Insulin Resistance. Journal of Diabetes & Metabolism 2011; 2(9).
 
[6]  Liu, Z., Chaowei, F., Weibing, W. and Biao, X. "Rersearch prevalence of chronic complications of type 2 diabetes mellitus in outpatients–a crosssectional hospital based survey in urban China." Health Qual Life Outcomes 8 (2010): 62.
 
[7]  Vaz F. M and Wanders R. Carnitine biosynthesis in mammals. Biochem. J. 2002; 361: 417-429.
 
[8]  Flanagan J, Simmons P, Vehige J, Willcox Mand Garrett Q.Role of carnitine in disease. Nutrition & Metabolism 2010; 7(30).
 
[9]  Dayanand C. D, Krishnamurthy N, Ashakiran S and Shashidhar K. N. Carnitine: a novel health factor–an overview. Int J Pharm Biomed Res 2011; 2(2): 79-89.
 
[10]  Kapoor P and Kapoor A. K. Coenzyme Q10–A novel molecule. Journal, Indian Academy of Clinical Medicine 2013; 14(1): 37-45.
 
[11]  Bonakdar R. A and Guarneri E. Co-enzym Q10. Complementary and alternative medicine 2005; 72(6):1065-70.
 
[12]  Kumar A, Kaur H, Devi P and Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacology & therapeutics 2009; 124(3): 259-268.
 
[13]  Ajjan R. Cardiovascular disease in diabetes: are we doing enough? Austin Journal of Endocrinology and Diabetes 2014; 1(2).
 
[14]  Unachukwu C and Ofori S. Diabetes mellitus and cardiovascular risk. The Internet Journal of Endocrinology 2012; 7(1).
 
[15]  American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 2014; 37(1): 14-80.
 
[16]  Mingrone G. Carnitine in type 2 diabetes. Annals of the New York Academy of Sciences 2004; 1033(1): 99-107.
 
[17]  Amin M. M, Asaad G. F, Salam R, El-Abhar H. S and Arbid M. S. Novel CoQ10 Antidiabetic Mechanisms Underlie Its Positive Effect: Modulation of Insulin and Adiponectine Receptors, Tyrosine Kinase, PI3K, Glucose Transporters, sRAGE and Visfatin in Insulin Resistant/Diabetic Rats.PloS one 2014; 9(2): e89169.
 
[18]  Hadadinezhad S, Ghazaleh N and Razavi Z. Effects of l-carnitine on glycemic control and C-peptide levels in patients with type 2 diabetes mellitus. Turk Jem 2008; 12: 1-3.
 
[19]  Rahbar A. R, Shakerhosseini R, Saadat N, Taleban F, Pordal A and Gollestan B. Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus. European journal of clinical nutrition 2005; 59(4): 592-596.
 
[20]  Abdel-aleem S, Sayed-Ahmed M, Nada M. A, Hendrickson S. C, St Louis J and Lowe J E. Stimulation of Non-oxidative Glucose Utilization byL-carnitine in Isolated Myocytes. Journal of molecular and cellular cardiology 1995; 27(11): 2465-2472.
 
[21]  Hodgson J. M, Watts G. F, Playford D. A, Burke V and Croft K. D. Original Communication-Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. European Journal of Clinical Nutrition 2002; 56:1137-1142.
 
[22]  Mezawa M, Takemoto M, Onishi S, Ishibashi R, Ishikawa T, Yamaga, M, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors 2012; 38(6): 416-421.
 
[23]  Anwar M, El-Moniem M. A, Megahed H. A, EL-Toukhy S. E, Mohammed N. A and Youness E. R. Effect of Coenzyme Q10 Supplementation on Markers of Oxidative Stress in Streptozotocin Induced Diabetic Rats. Journal of Applied Pharmaceutical Science 2014; 4(6):9-15.
 
[24]  Eriksson J. G, Forsen T. J, Mortensen S. A and Rohde M. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999; 9(2‐4): 315-318.
 
[25]  Mynatt R. L. Carnitine and type 2 diabetes. Diabetes/metabolism research and reviews 2009; 25(S1): 45-49.
 
[26]  Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L and Motta M. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. The American journal of clinical nutrition 2009; 89 (1), 71-76.
 
[27]  Alipour B, Barzegar A, Panahi F, Safaeian A and Es. haghi M. Effect of L-Carnitine Supplementation on Metabolic Status in Obese Diabetic Women with Hypocaloric Diet. Health Scope 2014; 2(4): e14615.
 
[28]  Gonzalez-Ortiz M, Hernandez-Gonzalez S. O, Hernandez-Salazar E and Martinez-Abundis E. Effect of oral L-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients. Annals of Nutrition and Metabolism 2008; 52(4): 335-338.
 
[29]  Derosa G, Cicero A. F, Gaddi A, Mugellini A, Ciccarelli L and Fogari R. The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clinical therapeutics 2003; 25 (5):1429-1439.
 
[30]  Sirtori C. R, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, et al. L-carnitine reduces plasma lipoprotein (a) levels in patients with hyper Lp (a). Nutrition, metabolism, and cardiovascular diseases: NMCD2000; 10(5): 247-251.
 
[31]  Tsimikas S and Hall J. L. Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. Journal of the American College of Cardiology 2012; 60 (8): 716-721.
 
[32]  Kostner K. Lipoprotein (a): Pathophysiology, Metabolism, Treatment Options. Austral - Asian Journal of Cancer 2007; 6 (3): 157-163.
 
[33]  Kei A andElisaf M. S. Nicotinic acid: Do we know how it works after 55 years of clinical experience. World J Pharmacol 2012 June 9; 1(3): 50-54.
 
[34]  Galvano F, Li Volti G, Malaguarnera M, Avitabile T, Antic T, Vacante M and Malaguarnera M. Effects of simvastatin and carnitine versus simvastatin on lipoprotein (a) and apoprotein (a) in type 2 diabetes mellitus. Expert Opin. Pharmacother. 2009; 10(12); 1875-82.
 
[35]  Mohammadi R. K, Hosseinzadeh-Attar M. J, Eshraghian M. R and Esteghamati A. Coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. 1st Tabriz International Life Science Conference and 12th Iran Biophysical Chemistry Conference 2013. Tabtiz University of medical sciences.
 
[36]  Garrido-Maraver J, Cordero M. D, Oropesa-Ávila M, et al. Coenzyme Q10 Therapy. Molecular Syndromology 2014; 5(3-4): 187-197.
 
[37]  Chew G. T, Watts G. F, Davis T. M,et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008; 31(8): 1502-1509.
 
[38]  Al-Attar, A. M. (2010). Hypolipidemic effects of coenzyme Q10 in experimentally induced hypercholesterolemic model in female rats. American Journal of Pharmacology and Toxicology, 5(1), 14-23.
 
[39]  Shojaei M, Djalali M, Khatami M, Siassi F and Eshraghian M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein (a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis 2011; 5(2): 114-118.
 
[40]  Cicero A, Derosa G, Miconi A, et al. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomedicine & pharmacotherapy 2005; 59(6): 312-317.
 
[41]  Groneberg D. A, Kindermann B, Althammer M, et al. Coenzyme Q< sub> 10</sub> affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. The international journal of biochemistry & cell biology 2005; 37(6): 1208-1218.
 
[42]  Singh R. B andNiaz M. A. Serum concentration of lipoprotein (a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. International journal of cardiology 1999; 68(1): 23-29.